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Background: Nuclear factor-κB (NF-κB) induces a variety of biological processes through transcriptional gene
control whose products are components in various signaling pathways. MicroRNAs are a small endogenous
non-coding RNAs that regulate gene expression and are involved in tumorigenesis. Using human cervical cancer
cell lines, this study aimed to investigate whether NF-κB could regulate miR-130a expression and the functions and
targets of miR-130a.
Methods: We used the HeLa and C33A cervical cancer cell lines that were transfected with NF-κB or miR-130a
overexpression plasmids to evaluate their effects on cell growth. We utilized bioinformatics, a fluorescent reporter
assay, qRT-PCR and Western blotting to identify downstream target genes.
Results: In HeLa and C33A cells, NF-κB and miR-130a overexpression promoted cell growth, but genetic knockdowns
suppressed growth. TNF-α was identified as a target of miR-130a by binding in a 3’-untranslated region (3’UTR) EGFP
reporter assay and by Western blot analysis. Furthermore, low TNF-α concentrations stimulated NF-κB activity and then
induced miR-130a expression, and TNF-α overexpression rescued the effects of miR-130a on cervical cancer cells.
Conclusions: Our findings indicate that TNF-α can activate NF-κB activity, which can reduce miR-130a expression, and
that miR-130a targets and downregulates TNF-α expression. Hence, we shed light on the negative feedback regulation
of NF-κB/miR-130a/TNF-α/NF-κB in cervical cancer and may provide insight into the carcinogenesis of cervical cancer.
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Nuclear factor-κB (NF-κB) is a nuclear transcription fac-
tor that regulates the expression of a large number of
genes associated with inflammation [1,2], tissue damage
and repair [3,4], cell differentiation [5,6], apoptosis [7,8]
and tumor growth [9,10]. NF-κB is composed of five dis-
tinct but structurally related subunits: RelA, RelB, c-Rel,
p50 and p52, and these five mature proteins can form
various homodimeric and heterodimeric combinations
[11,12]. The dimers remain in an inactive form in the
cytoplasm, sequestered by one of the IκB family mem-
bers, mainly IκBα. In canonical NF-κB signaling, nuclear
translocation of NF-κB is controlled by the signal-induced
degradation of IκBs. Exposure of cells to stimuli, such as
pro-inflammatory cytokines, activates the IκB kinase (IKK),* Correspondence: htang2002@yahoo.com
†Equal contributors
1Tianjin Life Science Research Center and School of Basic Medical Sciences,
Tianjin Medical University, No. 22 Qi-Xiang-Tai Road, Tianjin 300070, China
Full list of author information is available at the end of the article
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.which phosphorylates IκB, and IκB then becomes sus-
ceptible to ubiquitination and degradation through the
proteasome system. Free p50 and p65 or c-Rel then trans-
locate into the nucleus to activate related genes, and this
gene regulation occurs mainly through promoter element
binding [13,14]. Some pro-inflammatory cytokines, che-
mokines, and many oncogenes associated with tumor
development and progression are NF-κB activators,
including palmitic acid, the most abundant long chain
saturated fatty acid [15]. Furthermore, the mitochondrial
antiviral signaling (MAVS) protein can recruit several
TRAF proteins, and these proteins are associated with
NF-κB activation [16]. Another protein, protein-arginine
methyltransferase 5 (PRMT5), is overexpressed in many
cancers and promotes tumorigenesis by stimulating
NF-κB [17]. Though these activators, TNF-α acts as an
important proinflammatory cytokine to stimulate NF-κB
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cytokine, and increased TNF-α levels have been observed
in serum and other patient samples with inflammation
[19]. It is mainly produced by monocytes, macrophages,
initial hemorrhages and necrosis of tumor tissue [20,21].
TNF-α is a secreted protein, mature TNF-α protein plays
its role mainly through its receptors on the surface [22-24].
So far, TNF-α seem powerful to destroy tumor, but has
fallen short of expectations in clinical use as an anti-tumor
agent because of its indeterminacy at therapeutic doses.
The autocrine or paracrine TNF-α expression can make
the opposite effect, like some reports showed TNF-α play a
role in the promotion of cell growth in low concentration
[25,26]. Low doses of endogenous TNF-α produced by
normal epithelial cells or epithelial-derived cancer cells
can also act as a tumor promoter, in NSCLC cells, the
TNF-α expression may affect the normal lung adjacent to
the tumor [27], in human breast cancer cell, TNF-α en-
hanced invasiveness of the malignant cells dependent on
matrix metalloprotease [28], in ovarian cancer cells the
CXCR4 expression also in a TNF-α–dependent manner
[29]. Many studies have demonstrated the role of TNF-α
in cell proliferation, and some reports have shown that
TNF-α acts as an apoptotic mediator in some cell lines,
such as hematopoietic cells [30] and cartilage progenitor
cells [31]. This proapoptotic effect can be weakened by
other substances in the body, such as miRNAs. However,
little is known about the ability of miRNAs to regulate
TNF-α expression.
miRNAs are small non-coding RNAs that regulate gene
expression at the post-transcriptional level through transla-
tional repression or mRNA degradation. They exert con-
trol over approximately 60% of human genes associated
with development, cell differentiation, growth, motility and
apoptosis [32,33], which render miRNAs one of the most
abundant classes of regulatory molecules. Particularly in
malignancies, aberrant miRNA expression has emerged
as a hallmark of cancer [34]. Because each miRNA is
thought to regulate hundreds of mRNAs, and each mRNA
is also modulated by many miRNAs [35], the identification
of miRNA targets represents an important step in un-
derstanding miRNA function. miR-130a, a miRNA has
been shown to promote cell survival in several cell lines
through different signaling mechanisms [36-38], but its
mechanism of action and expression are still not clear in
cervical cancer.
In this study, we found that NF-κB and miR-130a
promoted cervical cancer cell growth. miR-130a dir-
ectly targeted the 3’UTR of TNF-α and repressed its
translation, and TNF-α activated NF-κB to upregulate
miR-130a expression. Thus, TNF-α can stimulate NF-κB
activity and enhance miR-130a levels, which then re-
duces TNF-α levels. Therefore, this NF-κB/miR-130a/
TNF-a/NF-κB feedback signaling pathway may playan important role in the growth regulation of cervical
cancer cells.
Materials and methods
Cell culture and transfection
The human cervical cancer cell lines HeLa and C33A were
grown in RPMI1640 medium (GIBCO BRL, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum
(FBS), 100 IU/ml of penicillin and 100 mg/ml of strepto-
mycin. The cell lines were incubated at 37°C in a humidi-
fied chamber supplemented with 5% CO2. Transfections
were performed using the Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. All transfections were performed in
three independent experiments.
Bioinformatics
miRNA targets were predicted using the following algo-
rithms: Target-Scan, PicTar, and MiRBase Targets.
Plasmid construction
To construct the pcDNA3/NF-κB vector expressing p50
subunit, we amplified a DNA fragment carrying p50 by
PCR using sense and antisense NF-κB primers, and then
the fragment was cloned into the pcDNA3 vector at the
EcoRI and Xhol restriction sites.
To construct the pSilencer/shR-NF-κB vector interfere
p50 subunit expression, a 70-bp double-stranded fragment
was obtained via an annealing reaction using two single-
strands. The fragment was then cloned into a pSilencer 2.1
vector plasmid (Ambion) at the BamHI and Hind III sites.
To construct a pcDNA3/pri-miR-130a vector express-
ing miR-130a, we amplified a DNA fragment carrying
pri-miR-130a from genomic DNA using sense and anti-
sense Pri-130a primers. The 3’UTR, including predicted
target sites, was amplified by PCR using TNF-α-3’UTR-
sense and -antisense primers, and the amplified sequence
was cloned into an expression plasmid (pcDNA3/EGFP)
downstream of the EGFP gene between the EcoRI and
BamHI restriction sites. Similarly, the 3’UTR containing
mutated miR-130a binding sites was amplified using PCR
site-directed mutagenesis and cloned into the pcDNA3/
EGFP plasmid between the same restriction sites with
TNF-α-3’UTR-mut-sense and -antisense primers. The
resulting vectors were designated as pcDNA3/EGFP-TNF-
α-3’UTR and pcDNA3/EGFP-TNF-α-3’UTRmut.
The human TNF-α mRNA lacking the 3’UTR was amp-
lified from human HeLa cell cDNA by PCR using sense
and antisense TNF-α primers, which are listed in Table 1,
and then cloned into the pcDNA3 vector at the EcoRI and
Xhol restriction sites, which created the pcDNA3/TNF-α
plasmid.
All DNA oligonucleotides used are listed in Table 1,
and all constructs were confirmed by DNA sequencing.
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HeLa and C33A cells were co-transfected with pcDNA3/
pri-miR-130a or ASO-miR-130a in a 48-well plate followed
by the pcDNA3/EGFP-TNF-α-3’UTR or pcDNA3/EGFP-
TNF-α-3’UTR-mut reporter plasmids. The RFP expression
vector, pDsRed2-N1 (Clontech, Mountain View, CA), was
used for normalization. Cells were lysed with RIPA 48 h
after transfection, and proteins were collected. EGFP and
RFP fluorescence intensities were determined using an
F-4500 fluorescence spectrophotometer (HITACHI, Tokyo,
Japan).
Cell viability assay
HeLa and C33A cells were seeded in 24-well plates over-
night and then transfected with plasmid (1 μg each) or
oligonucleotides (final concentration 200 nM). After-
wards, cells were trypsinized and counted, seeded in 96-
well plates (in triplicate) for an MTT assay at a density
of 8,000 cells/well (HeLa) or 10,000 cells/well (C33A),
and incubated at 37°C for 24 h. Then, at 24, 48 and 72 h
after cell seeding, 10 μl MTT (final concentration, 0.5 mg/
ml) was added, and the cells were maintained at 37°C for
another 4 h. The medium was removed, and the precipi-
tate was dissolved in 100 μl DMSO. After shaking for15 min, the absorbance at 570 nm (A570) was measured
using an uQuant Universal Microplate Spectrophotometer
(Bio-Tek Instruments, Winooski, USA).
Colony formation assay
Following transfection in 24-well plates as described
above, HeLa and C33A cells were counted and seeded in
12-well plates (in triplicate) at a density of 200 cells/well.
The plates were incubated at 37°C in a 5% CO2 humidi-
fied incubator. The culture medium was replaced every
3 days. After 14 days in culture, cells were stained with
crystal violet and counted. Colonies with at least 50 cells
were considered for quantification.
RNA preparation and Quantitative reverse transcrption
PCR (qRT-PCR)
Total RNA extracted from HeLa and C33A cells was using
the TRIZOL reagent (Invitrogen, Carlsbad, CA), according
to the manufacturer’s instructions. RNA extraction from
tissue samples was performed by using the mirVana
miRNA Isolation Kit (Ambion) according to the manufac-
turer’s instructions. To assess RNA integrity, a portion
each RNA sample was used for concentration and purity
measurements (A260 and A280 by spectrophotometry),
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trophoresis in a 1% agarose gel stained with ethidium
bromide.
qRT-PCR used to detect the miRNA and mRNA levels
and was performed using an iQ5 real-time PCR detec-
tion system (Bio-Rad). Moloney murine leukemia virus
(M-MLV) reverse transcriptase (Promega, Madison, WI)
was used to reverse transcribe cDNA from RNA samples.
The SYBR Premix Ex Taq™ kit (TaKaRa, Otsu, Shiga, Japan)
was used to measure amplified DNA. Related primers
were purchased from AuGCT, Inc. (Beijing, China), and
sequences are shown in Table 1.
To detect miR-130a, 2 μg of total RNA (in triplicate)
was reverse transcribed to cDNA using M-MLV. U6 was
used as a housekeeping gene to normalize gene expres-
sion. The following PCR cycles were used: 94°C for 3 min
followed by 40 cycles of 94°C for 30 s, 56°C for 30 s, and
72°C for 30 s. To detect target genes, 5 μg of total RNA
(in triplicate) was reverse transcribed into cDNA. En-
dogenous β-actin gene levels were used as a control to
normalize gene expression. The following PCR cycles were
used: 94°C for 3 min followed by 40 cycles of 94°C for
30 s, 58°C for 30 s, and 72°C for 30 s.
Western blot
Western blotting was performed to determine protein
expression. Briefly, HeLa and C33A cells were transfected
with plasmid (4 μg each) or control oligonucleotides
(final concentration of 200 nM). After seeding in 25-ml
culture flasks, cells were washed with PBS and lysed
after 30 min in RIPA lysis buffer at 4°C to harvest total
protein. To collect nucleoproteins, cells were harvested
with PBS, centrifuged to obtain a cell precipitate, 0.4%
NP-40 added, and the cell precipitate resuspended. After
centrifugation, the supernatant contained the nucleo-
proteins. Next, 0.1% NP-40 was added to the remaining
cell precipitate, the precipitate was resuspended and
centrifuged, the supernatant was discarded, and the
remaining material resuspended in RIPA buffer to ob-
tain cytoplasmic proteins. Equal amounts of protein
were subjected to electrophoresis using a 10% SDS-
polyacrylamide gel under denaturing conditions and were
then transferred onto a nitrocellulose membrane. To
assess protein levels, membranes were incubated in
blocking buffer for 4 h at room temperature and then
with antibodies raised against p50 or TNF-α overnight
at 4°C. Membranes were then washed and subsequently
incubated with secondary antibody. Protein expression
was assessed by enhanced chemiluminescence and expos-
ure to chemiluminescent film. The LabWorks™ Image
Acquisition and Analysis Software (UVP, Upland, CA)
were used to quantify the protein band intensities. All
the antibodies were purchased from Tianjin Saier Biotech
(Tianjin, China).Immunofluorescent staining
Cells were seeded on 14-well slides at a concentration of
2000 cells/well and incubated overnight. After the cells
adhered to the slides, the culture medium was replaced
with medium containing TNF-α (Sigma-Aldrich, St. Louis,
MO) at a final concentration of 20 ng/mL, and the cells
were cultured for 24 h. Cells were fixed with 4% parafor-
maldehyde for 30 min, permeabilized with 0.5% Triton X-
100 for 5 min, and blocked with 10% donkey serum at
room temperature for 2 h. Following blocking, primary
antibodies were diluted in 1% normal donkey serum,
placed on the slide surface, and incubated at 4°C over-
night. Cells were washed, and a FITC-labeled donkey
anti-rabbit secondary antibody was diluted in 1% normal
donkey serum and added to the slides. Finally, DAPI was
used to stain the nuclei. Fluorescent images were acquired
using a Digital Sight DS-U1 scanning microscope (Nikon,
Tokyo, Japan) at an excitation wavelength of 488 nm. Im-
ages were superimposed using the NIS Elements F 2.20
imaging software (Nikon).
Tumor xenograft experiment
For in vivo tumor study, 3 × 106 Hela cells transfected
with pri-miR-130a and it is control vector were suspended
in 150 μl of serum-free 1640 for each mouse. Each mouse
(6 in each group, female, BALB/c-nu/nu at 6 weeks of
age) were implanted subcutaneously in the right armpit of
nude mice. All mice were killed 14 days after implant-
ation. The samples were frozen in liquid nitrogen or fixed
with phosphate-buffered neutral formalin. All studies were
performed under the American Association for the Ac-
creditation of Laboratory Animal Care guidelines for hu-
mane treatment of animals and adhered to national and
international standards. Ethical approval was given by the
medical ethics committee of the Ethics Committees of
Tianjin Medical University with the following reference
number: TMUhMEC 2011018.
Immunohistochemistry
The tissue samples were fixed in phosphate-buffered neu-
tral formalin, embedded in paraffin, and cut into 5 μm
thick sections. Tissue sections were deparaffinized, rehy-
drated, and microwave-heated in sodium citrate buffer for
antigen retrieval. The sections were then incubated with
0.3% hydrogen peroxide/phosphate-buffered saline for
30 min. Sections were incubated with a primary antibody
against TNF-α at a 1:50 dilution and incubated overnight at
4°C. Detection of the primary antibody was performed
using goat anti-rabbit-HRP for 1 hour at room temperature
and visualized with DAB substrate.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD).
Statistical analyses were performed with a paired t-test.
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were performed in triplicate, and one representative experi-
ment is shown in the Figures.
Results
NF-κB promotes the growth of human cervical cancer
cells
NF-κB has been shown to promote tumorigenesis, tumor
cell proliferation, invasion and metastasis [39]. To investi-
gate the role of NF-κB in cervical cancer cells, we con-
structed an NF-κB overexpression vector (pcDNA3/NF-κB)
and an NF-κB interference vector (pSilencer/shR-NF-κB)
which over express or knock down p50 protein that were
validated by western blot in transfected HeLa and C33A
cells (Figure 1A and B). Next, an MTT assay showed that
NF-κB overexpression increased HeLa and C33A cell via-
bility compared with the control group at 24, 48, and 72 h
after cell seeding (Figure 1C). Conversely, the knock down
of NF-κB suppressed cell viability (Figure 1D). The colony
formation assay also demonstrated that NF-κB overex-
pression increased HeLa and C33A colony numbers by
approximate 25% and 40%, respectively, compared with
the control vector (Figure 1E), but decreased NF-κB levels
reduced the colony numbers (Figure 1F). These results in-
dicate that NF-κB promotes cervical cancer cell viability
and growth.
NF-κB promotes human cervical cancer cell growth
through miR-130a
In our previous experimental work, gene chip results
showed some miRNAs which may regulated by NF-κB,
miR-130a was in them and relatively few existing reports
about it, so we picked it as our object of study for a further
explore. When HeLa and C33A cells were transfected with
pcDNA3/NF-κB or pSilencer/shR-NF-κB, qRT-PCR indi-
cated that NF-κB overexpression increased the miR-130a
levels by approximately 50% and 40% compared to that of
control vector, but a knock down of NF-κB decreased the
miR-130a levels by 25% in both HeLa and C33A cells, re-
spectively (Figure 2A). These results indicate that NF-κB
may induce miR-130a expression.
Some reports have shown that miR-130a can mediate
endothelial cancer cell growth [40,41], and our data also
showed that NF-κB enhanced the growth of cervical can-
cer cells and induced miR-130a expression. Thus, we spec-
ulated that miR-130a may mediate NF-κB’s cell growth
effects. First, we validated the efficiencies of pcDNA3/
pri-miR-130a or miR-130a antisense oligomers (ASO-
miR-130a). qRT-PCR revealed that cells transfected with
pcDNA3/pri-miR-130a produced 7.5 and 6-fold increases
in miR-130a levels. However, ASO-miR-130a reduced
miR-130a levels by almost 50% in transfected HeLa and
C33A cells (Figure 2B). Then, we performed MTT and col-
ony formation assays in transfected HeLa and C33A cellsand found that pcDNA3/pri-miR-130a increased cell via-
bility and the colony formation rate by approximately 20%
compared with the control group (Figure 2C and E).
Moreover, ASO-miR-130a led to a suppression of cell via-
bility and colony formation (Figure 2D and F) rate. These
results indicate that miR-130a facilitates HeLa and C33A
cell viability and growth, which is consistent with NF-κB’s
effects on HeLa and C33A cells.
As miR-130a and NF-κB plays the same role on the
growth of cancer cells, which prompt us miR-130a
maybe one of the regulatory mechanisms of NF-κB, in
order to verify this, we performed an experiment using
by NF-κB in cells with miR-130a knockdown. Results
showed that as miR-130a knockdown, cell growth ability
decreased compare with the group only overexpressed
NF-κB both in the MTT and colony formation assays
(Figure 2G and H).
miR-130a directly targets and negatively regulates TNF-α
expression
miRNAs regulate a number of cellular functions through
the downregulation of target gene expression by binding
to 3’UTRs. To predict candidate target genes of miR-
130a, we used three algorithm programs, TargetScan,
PicTar, and miRanda. Using these programs, we selected
TNF-α as a miR-130a target gene for further study be-
cause of its ability to suppress cancer cell growth and to
activate NF-κB. The complementary sequence between
the seed sequence of miR-130a and the TNF-α 3’UTR is
shown in Figure 3A. To elucidate miR-130a’s direct regu-
lation of TNF-α, an enhanced green fluorescent protein
(EGFP) reporter assay was used to identify the target site
in the TNF-α 3’UTR. We first constructed an EGFP re-
porter plasmid by inserting the miR-130a binding site in
the TNF-α 3’UTR downstream of the EGFP stop codon
(pcDNA3/EGFP-TNF-α-3’UTR) and a mutant seed se-
quence in a reporter plasmid (pcDNA3/EGFP-TNF-α-
3’UTR-mut). Next, HeLa and C33A cells were cotrans-
fected with the pcDNA3/EGFP-TNF-α-3’UTR reporter
plasmid and pcDNA3/pri-miR-130a or ASO-miR-130a
plasmids. We found that pcDNA3/pri-miR-130a expres-
sion led to a 25% decrease in EGFP fluorescence intensity
compared with the control group, and the EGFP fluores-
cence intensity in cells transfected with ASO-miR-130a in-
creased more than 25% (Figure 3B). However, there were
no significant changes in the fluorescence intensities of
the pcDNA3/EGFP-TNF-α-3’UTR-mut group regardless
of altered miR-130a levels (Figure 3C). Furthermore, we
examined endogenous TNF-α that had been downregu-
lated by miR-130a. Overexpression of miR-130a led to
an approximately 50% reduction in TNF-α mRNA levels,
but conversely, blocking miR-130a expression increased
TNF-α mRNA levels by approximately 50% (Figure 3D).
Western blot analysis showed that pcDNA3/pri-miR-130a
Figure 1 NF-κB promotes the growth of human cervical cancer cells. (A and B) Western blot analysis was utilized to detect NF-κB levels in
HeLa cells and C33A cells transfected with pcDNA3/NF-κB or pSilencer/shR-NF-κB. After transfecting both cell lines, cells were cultured for 48 h,
and then lysed for 30 min with RIPA buffer at 4°C. The endogenous GAPDH expression levels were used to normalize protein expression.
(C and D) The effects of NF-κB on cell viability was assessed by MTT assays. HeLa and C33A cells were detached from 24-well plates after
transfection with pcDNA3/NF-κB and pSilencer/shR-NF-κB or their respective control vectors. Relative cell growth was assessed at 24, 48 and 72 h after
seeding in 96-well plates. (E and F) The effects of NF-κB on colony formation. Cells were detached from 24-well plates after transfection and seeded in
12-well plates, and on the 14th day after seeding, the number of colonies was counted. Experiments were performed in triplicate. (*P < 0.05, **P < 0.01).
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Figure 2 miR-130a promotes the growth of human cervical cancer cells. (A) The effects of NF-κB on miR-130a expression. Real-time RT-PCR
was used to evaluate miR-130a levels in HeLa and C33A cells transfected with the pcDNA3/NF-κB or pSilencer/shR-NF-κB plasmids. Total RNA was
extracted 24 h post-transfection and used for reverse transcription and real-time PCR. U6 snRNA was used to normalize gene expression.
(B) Real-time RT-PCR was performed to detect the miR-130a levels in the two cell lines treated with pri-miR-130a or ASO-miR-130a. U6 snRNA was
used to normalize gene expression. (C and D) MTT assays were performed to determine the effects of miR-130a on cell viability. HeLa and C33A cells
were detached from 24-well plates after transfection with pcDNA3/pri-miR-130a or a control vector and ASO-miR-130a or control oligonucleotides,
and the relative cell growth was determined at 24, 48 and 72 h after seeding in 96-well plates. (E and F) The effects of miR-130a on cell proliferation
were evaluated by a colony formation assay. Cells were detached from 24-well plates after transfection and seeded in 12-well plates. On the 14th day
after seeding, the number of colonies was determined. (G and H) MTT and colony formation assays using by NF-κB in cells with miR-130a knockdown.
Experiments were performed in triplicate. (*P < 0.05, **P < 0.01).
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cells and 30% in C33A cells (Figure 3E), and blocking en-
dogenous miR-130a expression increased TNF-α protein
levels by 50% in both cells types (Figure 3F). We also
verified this result in vitro, cells were transfected with
pcDNA3/pri-miR-130a and its control vector then injected
subcutaneously in the flank and collected the tumor tis-
sue. In the RNA extracted from tissue, miR-130a was
increased compared to the control group (Figure 3G),
and staining of TNF-α was decline (Figure 3H). Altogether,
these results indicate that miR-130a can bind to the TNF-α
3'UTR and negatively regulate its mRNA and protein ex-
pression levels.
TNF-α overexpression counteracts the effects of miR-130a
To confirm that miR-130a promotes cervical carcinoma
cell growth through at least a partial downregulation of
TNF-α, we generated a TNF-α expression vector (pcDNA3/
TNF-α) lacking the TNF-α 3’UTR to minimize miRNA
interference. miR-130a was overexpressed with TNF-α in
HeLa and C33A cells, and then growth activity was exam-
ined by MTT and colony formation assays. Western blot
analysis showed that the miR-130a-induced reduction in
TNF-α levels was rescued by the pcDNA3/TNF-α plasmid
transfected into HeLa and C33A cells (Figure 4A and B).
In the colony formation assay, ectopic TNF-α expres-
sion abrogated the cell growth enhancement caused by
miR-130a compared with the control vector (Figure 4C
and D), but in the MTT assay, no obvious changes were
observed between the experimental and control groups
(Figure 4E and F). Therefore, these results provide further
evidence that TNF-α overexpression counteracts the re-
pressive effects of miR-130a on cell growth.
TNF-α stimulates NF-κB to upregulate miR-130a expression
to form a TNF-α/NF-κB/miR-130a feedback loop
TNF-α is a strong activator of NF-κB [42,43], and our
findings indicated that NF-κB could stimulate miR-130a
expression, which in turn downregulated TNF-α expres-
sion (Figure 5A). Therefore, we speculated that TNF-α
may regulate miR-130a expression through the NF-κB
pathway. Twenty-four hours after TNF-α treatment, weextracted cytoplasmic and nuclear proteins from HeLa
and C33A cells to detect NF-κB and found that the nu-
clear p50 content was significantly increased as assessed
by Western blot (Figure 5B). Immunofluorescent staining
also showed that TNF-α increased nuclear p50 (red) levels
with compared with the control (Figure 5C and D). In
Figure 2G and H, we seen NF-κB increased the growth
capacity of crvical cncer cells through miR-130a, and we
have demonstrated that miR-130a can direct targeting
TNF-α, so we made a transfection of ASO-miR-130a and
NF-κB, we found that the consume of miR-130a rescue
the reduction of TNF-α inducted by NF-κB (Figure 5E),
these results strongly support our hypothesis. Moreover,
TNF-α treatment upregulated miR-130a levels by approxi-
mately 5-6.5-fold in HeLa and C33A cells (Figure 5F).
Altogether, TNF-α initially stimulated NF-κB activation to
induce miR-130a expression, which in turn targeted and
down-regulated TNF-α expression and suggests a TNF-α/
NF-κB negative feedback loop acting through miR-130a in
cervical cancer cells (Figure 5G).
Discussion
NF-κB is one of the most important intracellular nuclear
transcription factors, and it plays a central role in the
transcriptional regulation of many genes that are influ-
enced by various stimuli. Some studies have shown that
NF-κB promotes tumorigenesis through transcriptional
regulation. NF-κB activation is involved in Ras-induced
carcinogenic effects and telomerase reverse transcriptase
activity [44-46], but it can also promote apoptosis [47-49].
Here, utilizing MTT and colony formation assays, we
demonstrated that NF-κB played a growth-promoting role
in the HeLa and C33A human cervical cancer lines.
miRNAs have been found to be involved in physio-
logical and pathological processes. Moreover, NF-κB has
been shown to regulate miRNA expression, and in turn,
some miRNAs modulate NF-κB expression directly or
indirectly [50,51]. We are interested in miRNA regula-
tion of the NF-κB signal pathway. Hence, we found that
NF-κB induced miR-130a expression to significantly
increase, whereas the knockdown of NF-κB repressed
miR-130a expression. Therefore, we conclude that NF-κB
Figure 3 miR-130a directly targets and negatively regulates TNF-α expression. (A) Wild type (wt) and mutant complementary TNF-α mRNA
3’UTR sequences are shown compared with the miR-130a sequence. (B and C) EGFP reporter assays were performed to confirm the direct
interaction of miR-130a and the TNF-α 3’UTR. HeLa and C33A cells were transfected with an EGFP reporter plasmid and the pcDNA3/pri-miR-130a
or ASO-miR-130a plasmids, and the EGFP intensity was measured. (D) In HeLa and C33A cells, TNF-α expression levels were measured by real-time
RT-PCR. The endogenous expression levels of β-actin mRNA were used to normalize mRNA expression. (E and F) Alterations in the TNF-α
protein levels. miR-130a was overexpressed or its endogenous expression was blocked in both cell lines, and total protein was harvested
for Western blot analysis. GAPDH protein expression levels were used to normalize the protein expression data. (G) HeLa and C33A cells
were transfected with pcDNA3/pri-miR-130a or control vector and then implanted subcutaneously in the right armpit of nude mice, collected tumor
after 14 days and made real-time RT-PCR assay to detect the expression levels of miR-130a in tumors. U6 snRNA was used to normalize gene
expression. (H) Immunohistochemistry detected the levels of TNF-α protein in cervical cancer overexpress miR-130a compare with the
control group. The histograms show the normalized mean ± SD mRNA levels and protein intensities from three independent experiments.
(*P < 0.05, **P < 0.01).
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Figure 4 TNF-α overexpression counteracts the effects of miR-130a. (A and B) Western blot analysis was used to determine TNF-α protein
levels and validate the TNF-α overexpression vector. HeLa and C33A cells were co-transfected with the pcDNA3/TNF-α plasmid, which did not
contain the TNF-α 3’UTR, with or without the pcDNA3/pri-miR-130a plasmid. GAPDH protein expression was used to normalize the endogenous
expression data. (C and D) Colony formation assays were performed to determine the effects of TNF-α on cell proliferation. We transfected the
pcDNA3/TNF-α vector with or without cotransfection of pcDNA3/pri-miR-130a as in Figure 2G and H. (E and F) MTT assay used to assess cell
viability. The data represent the mean ± SD of three independent experiments. (*P < 0.05, **P < 0.01).
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shown that miR-130a plays an important role in cell
function and carcinogenesis by targeting various genes,
such as FOG-2 [36], GAX [37] and Smad4 [38] in cardio-
myocytes, vascular smooth muscle cells and granulo-
cytic precursors cells, respectively. In cancer, miR-130a
targets MET in non-small cell lung carcinoma [40] and can
target ATG2B and DICER1 to kill Chronic Lymphocytic
Leukemia cells [41]. To determine whether miR-130a’s
effects on cervical cancer growth are downstream of
NF-κB, we used gain-of- and loss-of-function assays to
examine the role of miR-130a in cervical cancer cells.
MTT and colony formation assays showed that miR-130a
promoted HeLa and C33A cell viability and colony forma-
tion compared with the control, which is consistent with
NF-κB’s ability to enhance the growth of human cervical
cell lines.
miRNA possesses diverse roles that up- or down-regulate
target gene expression [52-57]. To identify the miR-130a
target genes responsible for its effects on cervical cancer
cells, we used bioinformatics and functional knowledge
associated with NF-κB and miR-130a and chose TNF-α
as a candidate gene for further study. In the EGFP re-
porter assay, the expression of an EGFP reporter plasmid
containing the TNF-α 3’UTR was repressed by miR-130a,
and the mutated TNF-α 3’UTR abolished this effect.
Furthermore, qRT-PCR and Western blot analysis showed
that miR-130a decreased TNF-α mRNA and protein
expression levels in cervical cancer cells compared with
the control. Together, these data suggest that miR-130a
downregulates TNF-α expression by binding to its 3’UTR.
Moreover, ectopic TNF-α expression lacking the 3’UTR
abrogated the effects of miR-130a on cervical cancer
cell growth in the colony formation assay, but cell
viability assessed by MTT assay was not obviously af-
fected. These effects may result from miR-130a’s regu-
lation of TNF-α requiring a certain length of time to
be effective or involving other target genes; however,
the detailed mechanism still needs to be investigated.
Therefore, we conclude that miR-130a promotes cell
growth through at least the partial involvement of
TNF-α.
Tumor necrosis factor-alpha has been reported to be
related to a variety of physiological processes, including
cytotoxicity and the regulation of anti-viral and immuneresponses, and most of these processes are regulated
through downstream regulatory factors [58,59]. Although
TNF-α can destroy tumors, in different environments,
it may possess other effects, even acting as an endogen-
ous tumor promoter [27-29,60]. TNF-α is a strong NF-κB
activator [61-63]. While high concentrations of TNF-α
can induce the death of cervical cancer cells [64-66],
we found that low TNF-α concentrations induced cer-
vical cancer cell growth. However, how NF-κB provides
feedback regulation of TNF-α expression is not well
known. Here, we found that TNF-α stimulated the
nuclear translocation of NF-κB and induced miR-130a
expression in HeLa and C33A cells. A recent report
showed that LPS could increase miR-130a expression,
and NF-κB was involved in this process in human bil-
iary epithelial cells [11]. Because LPS is a widely known
TNF-α activator, these results support our conclusions.
Thus, TNF-α stimulates NF-κB to induce miR-130a
expression, and in turn, miR-130a downregulates TNF-α
expression, which may form a feedback loop of TNF-α/
NF-κB/miR-130a/TNF-α. This negative feedback loop
may regulate TNF-α production to maintain relatively
low concentrations. These low TNF-α concentrations
may stimulate the nuclear translocation of NF-κB and en-
able cells to survive. Therefore, this NF-κB/miR-130a/
TNF-α feedback loop may contribute to low TNF-α
concentrations that avoid the induction of apoptosis
in carcinogenesis.
Conclusions
This study is the first to demonstrate that NF-κB and
miR-130a can promote the growth of human cervical
cancer cells and identifies TNF-α as a new target gene of
miR-130a. NF-κB can increase miR-130a expression, and
this enhancement of miR-130a expression inhibited TNF-
α expression, which is a direct target of miR-130a. Low
levels of TNF-α induced nuclear NF-κB translocation,
which caused a gradual decline in miR-130a expression.
Based on these results, we provide evidence of the exist-
ence of an NF-κB/miR-130a/TNF-α/NF-κB feedback loop
in cervical cancer cells (Figure 5G). Our experimental re-
sults may aid in the understanding of the molecular mech-
anisms involving NF-κB and tumorigenesis and might
provide a new potential biomarker of diagnostic and
therapeutic value for cervical cancer patients.
Figure 5 NF-κB inhibits TNF-α expression, and TNF-α increases NF-κB activity. (A) HeLa and C33A cells were transfected with pcDNA3/NF-κB,
and total protein from cells was collected to determine the TNF-α levels. The endogenous GAPDH expression levels were used to normalize protein
expression. (B) Cells were treated with TNF-α, and Western blot analysis was used to detect NF-κB activity. Cells were collected in PBS, centrifuged,
resuspended in 0.4% NP-40, and centrifuged again to obtain nucleoproteins. Nuclear protein CENPA were used to normalize protein expression.
(C and D) Cells were seeded on 14-well slides and stimulated with TNF-α (20 ng/mL) for 24 h. Next, cells were fixed with 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100, and blocked with 10% donkey serum. A primary antibody raised against p50 was diluted in 1% normal donkey
serum and incubated at 4°C overnight. Cells were washed, and a FITC-labeled donkey anti-rabbit antibody was diluted in 1% normal donkey serum.
Finally, DAPI was used to stain the nuclei. All the experiments were performed in triplicate. (E) Verify the role of miR-130a in the NF-kB induction of
TNF-α. Cells were transfected with pcDNA3/NF-κB and ASO-miR-130a compare pcDNA3/NF-κB and ASO-NC, the cells were collected totle protein for
Western Blot. GAPDH protein expression was used to normalize the endogenous expression data. (F) Cells were treated with TNF-α (20 ng/mL) for
24 h, and RNA was extracted for real-time RT-PCR. U6 snRNA was used to normalize gene expression. (G) The relationship between NF-κB, miR-130a
and TNF-α. (*P < 0.05, **P < 0.01).
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